Abstract Objectives: To determine¯uconazole population pharmacokinetics and explore the relationships between¯uconazole average concentration and treatment eectiveness or microbiological resistance induction during a study aimed at evaluating the ecacy, tolerability and resistance induction after secondary prevention with¯uconazole (150 mg weekly) versus placebo in human immunode®ciency virus-positive (HIV+) patients with oropharyngeal candidiasis. Methods: Population pharmacokinetic parameters of uconazole determined from 458 serum drug concentration measurements obtained over 37 months in 132 HIV+ patients not receiving highly active antiretroviral therapy. Mean estimates and variabilities were generated using non-linear regression analysis. Logistic and linear regression analyses were used to explore the relationships between the estimated average concentration of uconazole and candidiasis relapse or fungal resistance towards¯uconazole. Results: Fluconazole kinetics were best described by a one-compartment model with ®rst-order oral absorp tion from the gastrointestinal tract. The pharmacokinetics were in¯uenced only by body weight. No eect was observed for gender, age, height or lymphocyte CD4 counts. The mean apparent population clearance was 0.79 l/h, the volume of distribution 57 l and the absorption constant (k a ) 0.93 h ±1 . Inter-occasion variability in clearance (45%) was large relative to intersubject variability (21%). Taking into account the average¯uconazole concentration or the time above the minimal inhibitory concentrations did not clinically improve the prediction of the occurrence of oropharyngeal relapse or microbiological resistance. Conclusion: The relationship between¯uconazole concentrations and preventive eectiveness was poor. Together with the rather large inter-occasion variability in¯uconazole clearance, this suggests no role of therapeutic drug monitoring in optimising¯uconazole treatment for secondary prevention.
Introduction
Oropharyngeal candidiasis is observed in many human immunode®ciency virus-positive (HIV+) patients and still represents the most frequent opportunistic infection in HIV-infected individuals. The ecacy and safety of uconazole in the treatment of oral thrush associated with HIV infection has been demonstrated [1, 2] , but the frequency of relapses is high and increases with the patient immunode®ciency. The management of oropharyngeal candidiasis in HIV+ patients using a secondary prevention with¯uconazole (50±150 mg once a week) has thus been proposed, and the ecacy and safety of this approach are now established [3, 4, 5] . This strategy presents advantages with respect to cost, compliance and drug interactions [6] . However, increased resistance tō uconazole has been reported during prophylactic therapy [7] .
A prospective, double-blind, randomised, placebomatched study was conducted in a cohort of HIV+ patients over a period of 37 months to assess the eect of secondary prevention by weekly¯uconazole on the development of clinical and microbiological resistance tō uconazole (Pagani et al., unpublished observations). Blood samples were collected during this study primarily to assess patient's adherence to treatment. The aims of this analysis were to characterise the population pharmacokinetics of¯uconazole in this group of patients. As a secondary exploratory endpoint, we evaluated the relationships between the average blood concentrations or the time over the minimal inhibitory concentrations (MICs; according to a posteriori Bayesian estimation) and the probability of oropharyngeal candidiasis relapse or of clinical or microbiological resistance to¯uconazole.
Materials and methods

Patients
Data from 132 patients with 458 serum concentrations were available for the population pharmacokinetic analysis. The patients were randomised to receive orally either¯uconazole (150 mg weekly; n=66) or placebo (n=66). In case of candidiasis relapse, a treatment of¯uconazole (200 mg per day) was undertaken for 7 days. Serum samples were drawn at least every 3 months on follow-up visits and during candidiasis relapses to check for compliance. For convenience, blood samples were taken at each visit. No prede®ned sampling strategy was applied, but the exact time of the last administered dose was recorded by the physician at each visit to get accurate dosing information. In addition to accurate dosing information and time of sampling, the following data were collected for each patient: gender, body weight (BW), height, age, number of CD4 lymphocytes and serum creatinine concentration. There were 93 males and 39 females. Their body weights ranged from 41 kg to 97 kg (mean 61 kg), their height from 146 cm to 192 cm (mean 172 cm) and their age from 25 years to 63 years (mean 37 years). The serum creatinine concentration ranged from 53 lmol/l to 181 lmol/l (mean 83 lmol/l); the mean creatinine clearance estimated using the equation of Cockcroft and Gault [8] was 85 ml/min (®ve patients <60 ml/min). The CD4 lymphocytes ranged from 0/mm 3 to 605/mm 3 (mean 101/mm 3 ). The number of uconazole serum concentration measurements per patient was 2.7 (range 1±8).
Analytical methods
Serum¯uconazole concentrations were measured using reversephase high-performance liquid chromatography after solid-phase extraction, adapted from the method published by Inagaki [9] . The chromatographic equipment consisted of a Hewlett-Packard 1090 instrument (Series II; Hewlett-Packard, Germany) equipped with a spectrophotometric ultraviolet±visible (UV±VIS) diode-array detector (DAD) set at 200 nm. The separations were carried out on a Macherey-Nagel ChromCart 125/4 Nucleosil 100 C18AB (DuÈ ren, Germany) using an isocratic elution of acetonitrile + 0.1% acetic acid/bidistilled water (17/83) for 10 min at a¯ow rate of 1 ml/min, followed by rinsing and equilibration steps. The calibrations, using the internal standard method (UK-54373) are linear (r 2 >0.999) over the 0.1-to 25-mg/l concentration range. The detection limit was 0.1 mg/l. Quality control samples at 0.75-, 7-and 20-mg/l concentrations had, overall, an inter-day relative standard deviation within 1.4±7.5%. The mean inter-assay deviations from their nominal concentrations were comprised within the range ±3.3% to +0.4%. Calculated precision and accuracy of the analytical method were therefore in accordance with the 15% recommendations of the Conference Report on Bioanalytical Method Validation [10] .
Population pharmacokinetic analysis
The analysis was performed using the computer program NON-MEM, version V, developed by Beal and Sheiner [11] . It uses mixed-eects (®xed and random) non-linear regression modelling to estimate the mean and the variance of the pharmacokinetic parameters in the study population and factors that may in¯uence them. A stepwise procedure was used to ®nd the model that best ®tted the data. First, we compared one-and two-compartment models with ®rst-or zero-order absorption. The in¯uence of each recorded patient characteristics on the kinetic parameters was tested sequentially. A proportional error distribution was assumed for the inter-individual variability of the pharmacokinetic parameters of the form shown below: No covariance was assumed between the parameters.
To allow for an evaluation of pharmacokinetic±pharmacody-namic relationships, an additional inter-occasion variability g
clearance, although only one concentration sample per occasion was available, thus making inter-occasion and intra-individual variabilities confounded. The equation of the inter-individual and interoccasion variability of the j th subject was expressed as follows [12] :
The parameter Occ n takes the value of 1 on the n th occasion and 0 otherwise, and the occasion-related variations, g 2ij to g nij , are constrained to have the same variance. An additive and proportional error distribution was assumed for description of the intraindividual (residual) variability: Y j F j F j Á e 1j e 2j where F j is the model prediction concentration for the j th individual, 1 and 2 are the residual intra-individual error terms with mean zero and variance r 2 . All drug concentration data below the detection limit were set to half the detection limit. To limit their in¯uence, the variance of the additive intra-individual error component was forced to equal or exceed the squared half of the detection limit. the dierence in the minimum value of the objective function (DOF) was used to compare two models.
For model selection, we compared the plots of predicted response versus observations and used the Akaike criterion [13] . In addition, the following goodness-of-®t parameters were considered when choosing between models: residual plots, standard error and correlation matrix of the parameter estimates, size of the interindividual variance of the pharmacokinetic parameters, and size of the residual error. A simulation based on the pharmacokinetic results including 1000 individuals was performed using NONMEM to calculate the 95% predicted interval depicted in Fig. 1 . The concentrations at the 2.5th and 97.5th percentile at each time point were retrieved to construct the prediction interval.
Analysis of eect data
Oropharyngeal candidiasis relapse was determined clinically and con®rmed by means of bacteriological examinations (direct examination, primary strain isolation, identi®cation of colonies). The susceptibility of Candida Albicans towards¯uconazole was determined at each visit with a disk diusion agar test using 50 lḡ uconazole [7] . The inhibition diameter (mm) was measured, and microbiological resistance was de®ned as an inhibition diameter on an agar plate smaller than 25 mm.
The individual average concentrations of¯uconazole were estimated using the post-hoc estimates of clearance. Both the area under the concentration±time curve (AUC) and the time over the MIC (de®ned as 0.39 mg/l for C. albicans) were used for the statistical analysis. The AUC was de®ned as D ose /CL and the time above MIC was simulated using the post-hoc individual pharmacokinetic estimates in the software program Excel (version 7, Windows 98). The relationship between¯uconazole AUC or time above MIC and candidiasis relapses was assessed using logistic regression. To take into account a potential dierence in the time until relapse between both groups, a weighting variable was also introduced in the analysis. The independent variables were treatment (¯uconazole or placebo) and¯uconazole AUC or time above MIC, the dependent variable the candidiasis relapse and the weighting variable the logarithm of the time until relapse. The resistance to treatment was assessed using linear regression, with the inhibition diameter (mm) de®ned as the dependent variable and treatment (nested within subject) and¯uconazole AUC or time above MIC as the independent variables. All the standard statistical tests were performed using the Statistix software (version 4.1).
Results
Population pharmacokinetic analysis
A one-compartment model with ®rst-order absorption from the gastrointestinal tract was found to describe the data adequately (two-vs one-compartment model: DOF=0.0, Dn par =2). The absorption kinetics were dicult to estimate with precision since only trough concentration samples were generally taken. An intersubject variability was assigned on apparent clearance (CL) (DOF=±17.0, Dn par =1) and on apparent volume of distribution (V d ) (DOF=±7.9, Dn par =1). Without any covariates, the population estimate of CL was 0.65 l/h. The inter-subject variability in this parameter, expressed as percentage coecient of variation (CV%), was 34%; when allowing for an inter-subject and inter-occasion variability, the CV values were 30% and 45%, respectively (DOF=±186.0). The mean population V d (CV%) was 70.7 l (30%). The absorption was rapid, with a halflife of 42 min. The additive and proportional intrasubject variability were 0.78 mg/l (SD) and 34% (CV%), respectively.
Covariates assessment
The relationship between various covariates and the individual estimates of¯uconazole CL and V d were examined. Body weight signi®cantly in¯uenced both the CL and the V d of¯uconazole (DOF>±14.4, Dn par =1), reducing the CL variability from 34% to 31% and explaining the overall variability on the V d . The regression model for¯uconazole CL and V d accounting for BW was CL=0.79+1.1´BWE and V d =87.4+44.2´BWE, where BWE expresses the relative deviation of the individual BW from the mean BW in the population (BWE=±1+BW/mean BW). No eect of age (DOF= ±0.3, Dn par =1) or gender (DOF=0.0, Dn par =1) was observed. The number of lymphocytes CD4 and the height in¯uenced the CL of¯uconazole (DOF>±3.3, Dn par =1) but did not remain statistically signi®cant in the multivariate analysis (DOF=±1, Dn par =1), being too highly correlated with body weight. Similarly, no eect of creatinine CL on¯uconazole CL was observed (DOF=±0.3, Dn par =1). The remaining inter-subject and inter-occasion variabilities in CL were, respectively, 21% and 45%. The values of the population parameters for the ®nal regression model are given in Table 1 . Plasma concentrations of¯uconazole with population prediction and 95% prediction interval are presented in Fig. 1 .
Fluconazole eects
The population pharmacokinetic analysis was used to assess whether taking into account either the average concentration of¯uconazole or the time above MIC could improve the prediction of the response to¯uco-nazole prophylactic treatment. As assessed by Pagani et al. (unpublished observations), signi®cantly more patients experienced a relapse in the placebo than in thē uconazole group (90% vs 61%, P=0.001). The averagē uconazole concentration failed to improve the prediction of the response (P=0.7), even while using the time interval to relapse as a weighting variable (P=0.5). Similarly, the time above MIC failed to predict the response (P=0.8). A tendency to a signi®cant dierence could be detected between both groups for the occurrence of microbiological resistance in Candida isolates (P=0.03). However, when considering the millimetres of inhibition measured in the disk diusion agar test, a dierence of 3.2 mm diameter was noticed between the placebo (mean 46.5 mm) and the¯uconazole (43.3 mm, P<0.0001) groups. This trend towards some decrease in susceptibility to¯uconazole is however small, far from the cut-o value of 25 mm de®ned for microbiological resistance to treatment and, therefore, probably not clinically signi®cant. Here, again, taking into account the average¯uconazole concentration or the time above MIC did not improve statistically the prediction of this eect.
Discussion and conclusions
This study determined the population pharmacokinetics of¯uconazole and demonstrated that only BW but not gender nor any of the other studied covariates in¯uences uconazole pharmacokinetics. Intra-individual as opposed to inter-subject variability in CL was rather large, and individual¯uconazole concentrations did not correlate with therapeutic outcome, indicating that therapeutic drug monitoring would probably not improve use eectiveness of¯uconazole.
The mean population pharmacokinetic parameter estimates were in the same range as those already reported [14, 15, 16, 17] . Although a previous study reported no eect of BW on¯uconazole pharmacokinetics [16] , in this study BW signi®cantly in¯uenced¯uconaz-ole CL and V d . In contrast to previous studies [16, 18] , this study included female and male patients. Since neither the covariate plots suggested any gender dierences nor the inclusion of additional parameters for gender dierences in CL and/or V d improved the ®t, a clinically relevant eect of gender on¯uconazole pharmacokinetics can be excluded.
A reduction in¯uconazole dose was previously suggested for people with HIV infection who are seriously ill and/or who have compromised renal function [16, 18] . However, in this study, after inclusion of BW, neither lymphocyte CD4 count nor creatinine CL exhibited a signi®cant eect on¯uconazole CL. The initially detected statistical signi®cance of CD4 counts in our analysis probably occurred due to an inverse correlation of lymphocyte CD4 counts ± as a marker surrogate of disease progression ± and BW. A possible explanation why this study failed to detect a relevant eect of creatinine CL on¯uconazole CL, despite the fact that uconacole is mainly excreted unchanged renally, might be that this study included only a few patients with moderately impaired and nobody with severely impaired renal function. Therefore, a dose reduction in patients with considerably impaired renal function still seems justi®ed, although we would not recommend the same for patients with low CD4 counts.
In contrast to a previous population pharmacokinetic study on¯uconazole, which mainly included only one sampling occasion per patient, this study included blood sampling on several occasions for most patients. This sampling schedule allowed us to distinguish between inter-subject and inter-occasion variability. After inclusion of the covariate BW, the remaining intersubject variability was rather small compared with the inter-occasion variability. No relationship between the patients average¯uconazole concentration and the occurrence of oropharyngeal relapse or clinical or microbiological resistance could be detected. The large inter-occasion variability of pharmacokinetics might explain why drug concentrations at one occasion failed to explain overall¯uconazole response. However, also, the sparse sample collection may have compromised the power of the study to detect association of limited strength. In conclusion, this study demonstrated that uconazole pharmacokinetics are gender independent and do not depend on CD4 counts. The rather large inter-occasion variability in¯uconazole CL and the absent correlation between drug exposure and treatment response suggests that therapeutic drug monitoring does not represent a sensible approach for improving¯uco-nazole's therapeutic eectiveness. Residual intra-individual variability of the serum concentration, expressed as standard deviation (add, SD mg/l) and coecient of variation (prop, CV%)
